People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes ...

Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and Mounjaro, have become popular medications for controlling diabetes and treating obesity — but new Canadian research ...

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...

Coverage for GLP-1s (that’s glucagon-like peptide-1 receptor agonists) and other weight management medications is still somewhat limited. In most cases, insurance companies only cover these meds ...

The hormone glucagon-like peptide 1 (GLP-1) is released to help stimulate the production of insulin and the uptake of glucose in muscle and other tissues.

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic ...

Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study. Association between type of BRCA1/2 pathogenic/likely ...